© Copyright 2022 Alle Rechte vorbehalten. | Die Translationale Plattform HIV – Powered by IDCohorts
2021
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021 May 1;35(6):869-882. doi: 10.1097/QAD.0000000000002811. PMID: 33443370.
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus
Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d’Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 Oct 5;73(7):e2323-e2333. doi: 10.1093/cid/ciaa1878. PMID: 33354721.
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, Guaraldi G, Vehreschild JJ, Wit F, Law M, Wasmuth JC, Chkhartishvili N, d’Arminio Monforte A, Fontas E, Vesterbacka J, Miro JM, Castagna A, Stephan C, Llibre JM, Neesgaard B, Greenberg L, Smith C, Kirk O, Duvivier C, Dragovic G, Lundgren J, Dedes N, Knudsen A, Gallant J, Vannappagari V, Peters L, Elbirt D, Sarcletti M, Braun DL, Necsoi C, Mussini C, Muccini C, Bolokadze N, Hoy J, Mocroft A, Ryom L. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021 Nov;8(11):e711-e722. doi: 10.1016/S2352-3018(21)00163-6. Epub 2021 Sep 20. PMID: 34555326.
Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used
Matthias C Mueller, Susanne Usadel, Winfried V Kern, Andreas Zirlik, Qian Zhou. Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. Int J STD AIDS. 2021 Jul 7:9564624211029392. doi: 10.1177/09564624211029392. Epub ahead of print. PMID: 34233537.
2020
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Günthard HF, Necsoi C, Law M, Mussini C, Castagna A, Monforte AD, Pradier C, Chkhartisvilli N, Reyes-Uruena J, Vehreschild JJ, Wasmuth JC, Sönnerborg A, Stephan C, Greenberg L, Llibre JM, Volny-Anne A, Peters L, Pelchen-Matthews A, Vannappagari V, Gallant J, Rieger A, Youle M, Braun D, De Wit S, Petoumenos K, Borghi V, Spagnuolo V, Tsertsvadze T, Lundgren J, Ryom L; RESPOND study group. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS One. 2020 Dec 31;15(12):e0243625. doi: 10.1371/journal.pone.0243625. PMID: 33382756; PMCID: PMC7774984.
Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-2018
Stecher M, Chaillon A, Stephan C, Knops E, Kohmer N, Lehmann C, Eberle J, Bogner J, Spinner CD, Eis-Hübinger AM, Wasmuth JC, Schäfer G, Behrens G, Mehta SR, Vehreschild JJ, Hoenigl M. Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-20181. Emerg Infect Dis. 2020 Oct; 26(10):2439-2443. doi: 10.3201/eid2610.191506. PMID: 32946725; PMCID: PMC7510719.
Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017
Stecher M, Schommers P, Kollan C, Stoll M, Kuhlendahl F, Stellbrink HJ, Wasmuth JC, Stephan C, Hamacher L, Lehmann C, Boesecke C, Bogner J, Esser S, Fritzsche C, Haberl A, Hoffmann C, Jensen B, Schwarze-Zander C, Platten M, Fätkenheuer G, Schmidt D, Gunsenheimer-Bartmeyer B, Vehreschild JJ; ClinSurv Study Group. Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. Infection. 2020 Oct;48(5):723-733. doi: 10.1007/s15010-020-01469-6. Epub 2020 Jul 1. PMID: 32613529; PMCID: PMC7519003.
Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials
Stecher M, Classen A, Klein F, Lehmann C, Gruell H, Platten M, Wyen C, Behrens GMN, Fätkenheuer G, Vehreschild JJ. Systematic Review and Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. Clin Infect Dis. 2020 Mar 17;70(7):1406-1417.
Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Suárez I, Rohr S, Stecher M, Lehmann C, Winter S, Jung N, Priesner V, Berger M, Wyen C, Augustin M, Malin JJ, Fischer J, Horn C, Neuhann F, Püsken M, Plum G, Fätkenheuer G, Rybniker J. Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis. Infection. 2020 Nov 2:1–9. doi: 10.1007/s15010-020-01541-1. Epub ahead of print. PMID: 33140838; PMCID: PMC7605464.
HEnRY: a DZIF LIMS tool for the collection and documentation of biomaterials in multicentre studies
Heinen S, Schulze N, Franke B, Klein F, Lehmann C, Vehreschild MJGT, Gloistein C, Stecher M, Vehreschild JJ. HEnRY: a DZIF LIMS tool for the collection and documentation of biomaterials in multicentre studies. BMC Bioinformatics. 2020 Jul 8;21(1):290. doi: 10.1186/s12859-020-03596-1. PMID: 32640981; PMCID: PMC7346399.
Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility
Mysior P, Tenberken E, Stecher M, Vehreschild JJ, Schafberger A, Perea I, Brillen AL, Bartmeyer B, Esser S, Bremer V, Marcus U, Hoffmann D, Streeck H. Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility. AIDS Res Hum Retroviruses. 2020 Sep;36(9):721-733. doi: 10.1089/AID.2019.0237. Epub 2020 May 11. PMID: 32164425.
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting
Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Öllinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Puhr R, Chkhartishvilli N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):240-250. doi: 10.1097/QAI.0000000000002250. PMID: 31923088.
2019
Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany
Stecher M, Chaillon A, Eis-Hubinger AM, Lehmann C, Fätkenheuer G, Wasmuth JC, Knops E, Vehreschild JJ, Mehta SR, Hoenigl M. Pretreatment Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Transmission Clusters of the Cologne-Bonn Region, Germany. Clin Microbiol Infect 2019; 25(2): 253.e1-53.e4.
Hotspots of Transmission Driving the Local Human Immunodeficiency Virus Epidemic in the Cologne-Bonn Region, Germany
Stecher M, Hoenigl M, Eis-Hubinger AM, Lehmann C, Fätkenheuer G, Wasmuth JC, Knops E, Vehreschild JJ, Mehta SR, Chaillon A. Hotspots of Transmission Driving the Local Human Immunodeficiency Virus Epidemic in the Cologne-Bonn Region, Germany. Clin Infect Dis 2019; 68(9): 1539-46.
2018
Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016
Stecher M, Schommers P, Schmidt D, Kollan C, Gunsenheimer-Bartmeyer B, Lehmann C, Platten M, Fätkenheuer G, Vehreschild JJ, on behalf of the ClinSurv Cohort. Antiretroviral Treatment Indications and Adherence to the German-Austrian Treatment Initiation Guidelines in the German ClinSurv HIV Cohort Between 1999 and 2016. Infection 2018.
Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions – Cologne/Bonn, Munich and Hannover, 1999-2016
Stecher M, Chaillon A, Eberle J, Behrens GMN, Eis-Huebinger AM, Lehmann C, Jablonka A, Bogner J, Fätkenheuer G, Spinner C, Wasmuth JC, Kaiser R, Metha SR, Vehreschild JJ, Hoenigl M. Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions – Cologne/Bonn, Munich and Hannover, 1999-2016. Sci Rep 2018; 8(1): 6799.
2017
Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany
Schwarze-Zander C, Draenert R, Lehmann C, Stecher M, Boesecke C, Sammet S, Wasmuth JC, Seybold U, Gillor D, Wieland U, Kümmerle, T, Strassburg CP, Mankertz A, Eis-Hübinger AM, Jäger G, Fätkenheuer G, Bogner JR, Rockstroh JK, Vehreschild JJ. Measles, Mumps, Rubella and VZV: Importance of Serological Testing of Vaccine-Preventable Diseases in Young Adults Living with HIV in Germany. Epidemiol Infect 2017; 145(2): 236-44.
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-e356. doi: 10.1016/S2352-3018(17)30066-8. Epub 2017 May 10. PMID: 28501495; PMCID: PMC5555438.